Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Thursday

Bicara Therapeutics (NASDAQ:BCAX) is expected to announce its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 12:30 PM ET.

Bicara Therapeutics Price Performance

BCAX opened at $18.41 on Thursday. Bicara Therapeutics has a 12 month low of $7.80 and a 12 month high of $20.25. The stock has a market capitalization of $1.01 billion, a P/E ratio of -8.22 and a beta of -0.78. The business has a 50 day simple moving average of $16.93 and a 200-day simple moving average of $16.21.

Insider Buying and Selling

In other news, COO Ryan Cohlhepp sold 17,392 shares of the business’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $18.16, for a total value of $315,838.72. Following the completion of the transaction, the chief operating officer directly owned 205,141 shares of the company’s stock, valued at $3,725,360.56. The trade was a 7.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider David Raben sold 16,300 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total value of $301,876.00. Following the sale, the insider directly owned 55,286 shares in the company, valued at approximately $1,023,896.72. The trade was a 22.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 113,769 shares of company stock worth $2,133,453. 15.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of BCAX. AQR Capital Management LLC acquired a new position in shares of Bicara Therapeutics in the first quarter valued at approximately $248,000. Woodline Partners LP boosted its position in Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after acquiring an additional 72,998 shares during the last quarter. Geode Capital Management LLC grew its stake in Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after acquiring an additional 180,833 shares during the period. JPMorgan Chase & Co. raised its holdings in Bicara Therapeutics by 26.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock valued at $255,000 after acquiring an additional 5,664 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after acquiring an additional 1,233 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have issued reports on BCAX shares. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Citizens Jmp started coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set a “market perform” rating and a $31.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Friday, January 9th. HC Wainwright reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Finally, UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Six analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Bicara Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $30.25.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.